BioPharma Resources

Drug Trial Radar · NCT04494503

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

123

Planned (sponsor's estimate)

Start

Aug 31, 2020

Primary completion

Oct 20, 2024

Study completion Dec 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • APG-2575Drug

    APG-2575 orally once daily, every 28 days as a cycle.

  • RituximabDrug

    Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.

  • IbrutinibDrug

    Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events of APG-2575 single agentTime frame: Up to 6 cycles (each cycle is 28 days).
  2. Objective Response Rate (ORR) of APG-2575 single agentTime frame: Up to 6 cycles (each cycle is 28 days).
  3. Dose Limiting Toxicities (DLT) of combination therapyTime frame: 28 days.
  4. Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)Time frame: 28 days.

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Henan Provincial Oncology Hospital

    Zhenzhou, Henan, China · Recruiting

  • Union Hospital medical college Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China · Recruiting

  • The First affiliated hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First affiliated hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Fudan University Zhongshan Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Hangzhou, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.